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Amyloidosis is a pathologic process caused by 
GHSRVLWRI¿EULOODUDP\ORLGSURWHLQLQWKHH[WUDFHOOXODU
space.1 Amyloid protein has antiparallel ß-pleated sheet 
FRQ¿JXUDWLRQDQGFDQEHLGHQWL¿HGLQELRSV\VSHFLPHQ
using electron microscope or red Congo stain or 
WKLRÀDYLQH72 Amyloidosis can occur in various organs, 
such as heart, kidney, nerve, or gastrointestinal tract.1,2
The worldwide yearly incidence of amyloidosis is 
0.5-1.3/100,000 people with distribution as follow: 80% 
primary amyloidosis, 5-10% hereditary amyloidosis, 
$%675$&7
$P\ORLGRVLVLVDGLVHDVHPDUNHGE\GHSRVLWLRQRIPLVIROGHGSURWHLQVNQRZQDVDP\ORLGVLQWKHH[WUDFHOOXODU
VSDFHLQFOXGLQJJDVWURLQWHVWLQDOWUDFW$FFRUGLQJWRWKHSUHFXUVRUSURWHLQDP\ORLGRVLVLVFODVVL¿HGLQWRVL[W\SHV
all of which can be involved in the gastrointestinal tract. Amyloidosis has weight loss and gastrointestinal bleeding 
as the most frequent symptoms. Gastrointestinal tract biopsy is diagnostic in most cases of amyloidosis and 
&RQJRUHGVWDLQLVXVHGWRFRQ¿UPWKHDP\ORLGSURWHLQVGHSRVLW7UHDWPHQWRIDP\ORLGRVLVFRQVLVWVRIFRQWUROOLQJ
symptoms, terminating protein formation and deposit, and treating the underlying diseases. Chemotherapy might 
be applied depends on the type of amyloidosis. 
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Amiloidosis adalah suatu penyakit yang ditandai oleh penumpukan protein yang mengalami kesalahan 
pelipatan, yakni amiloid, di ruang ekstraselular, termasuk di saluran cerna. Berdasarkan protein prekursor, 
amiloidosis dibagi menjadi enam tipe, dimana setiap tipe tersebut dapat terlibat dalam saluran cerna. Penurunan 
berat badan dan perdarahan saluran cerna merupakan gejala klinis amiloidosis tersering. Biopsi saluran 
cerna bersifat diagnostik pada kebanyakan kasus amiloidosis dan pewarnaan Congo merah digunakan untuk 
memastikan adanya penimbunan protein amiloid. Tatalaksana amiloidosis terdiri dari pengontrolan gejala, 
penghentian pembentukan dan penimbunan protein, dan pengobatan dari penyakit yang mendasari. Kemoterapi 
dapat digunakan tergantung pada tipe amiloidosis.
Kata kunci: amiloidosis, diagnosis, tatalaksana
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2-3% secondary amyloidosis, 2% senile amyloidosis, 
and 8% localized amyloidosis. Sixty percent of primary 
amyloidosis patients are 50 to 70 years old patients. 
Secondary amyloidosis is more common in women, 
probably due to rheumatoid arthritis disease is more 
common in women.7
The frequency of gastrointestinal tract involvement 
varies with the type of amyloidosis. Gastrointestinal 
involvement is 55% in patient with secondary 
amyloidosis and 70% in patient with primary 
amyloidosis.3 Only 10-20% of gastrointestinal 
amyloidosis are localized.8 In other recent research, 
within 60 systemic amyloidosis cases, 50 (83%) cases 
are primary amyloidosis, 5 (8%) cases are hereditary 
amyloidosis with precursor protein, and 5 (8%) cases 
are senile amyloidosis.9
$0</2,'26,6&/$66,),&$7,21
Amyloid protein is a transformed low molecular 
weight protein. According to the precursor protein, 
amyloidosis is divided into 6 types. Amyloidosis 
nomenclature starts with letter “A” (for amyloid), 
followed by precursor protein description.3 The types 
of amyloidosis are as follow:
 Primary amyloidosis or AL
 The precursor proteins are light-chain monoclonal 
LPPXQRJOREXOLQV ț DQG Ȝ$P\ORLGRVLV FDQ
occur individually or coincidently with plasm 
cell malignancy, such as multiple myeloma or 
waldenstorm macroglobulinemia.2,3
 Secondary/reactive amyloidosisor AA
 The precursor protein are acute-phase serum 
amyloid A proteins (A-SAAs), secreted during 
acute phase of LQÀDPPDWLRQ. This amyloidosis 
occurred in diseases with high level of acute-phase 
UHDFWDQWVXFKDVLQÀDPPDWRU\GLVHDVHV)RUW\HLJKW
percent of AA patients have rheumatoid arthritis; 
in contrary, the incidence of amyloidosis in 
rheumatoid arthritis is 7-21%. AA may also occur 
LQRWKHULQÀDPPDWRU\GLVHDVHVVXFKDV&URKQ¶V
disease, ankylosing spondylitis, Reiter syndrome, 
psoriasis, progresive systemic sclerosis, primary 
biliary cirrhosis, systemic lupus erythematosus, 
or chronic infection (tuberculosis, syphilis, 
pyelonephritis, osteomyelitis, parasite infection).3,4
 Amyloidosis associated with hemodialysis
 Precursor protein is ß2 microglobulin, which is 
a molecular component of class I MHC in all 
nucleated cells. ß2 microglobulin is detained in 
the circulation due to decrease renal function of 
excretion, then transformed into amyloid protein. 
ß2 microglobulin just able be cleared by the kidney 
and cannot pass through dialysis membrane. The 
symptoms usually happen after 5 years.3,5
 Hereditary amyloidosis
 Precursor protein is an abnormal protein due 
to gen mutation.The most common type of this 
amyloidosis is ATTR (precursor protein is abnormal 
transthyretin) and AFib (precursor protein is 
DEQRUPDO Į¿EULQRJHQ FKDLQ7KHPXWDWLRQ FDQ
occurred in gen encoding apolipoprotein AI and 
lysozyme.3,6
 Senile amyloidosis
 Precursor protein is transthyretin, which is not 
abnormal inherited transthyretin. This amyloidosis 
mainly found in patients aged over 80 years. The 
protein deposition is in the heart or gastrointestinal 
tract.3,6
 Localized amyloidosis
 Precursor protein is hormonal or pro-hormonal 
protein. This amyloidosis is in the malignancy 
producing hormonal or pro-hormonal protein such 
as medullary thyroid carcinoma, prolactinoma, or 
insulinoma.6,7
3$7+2*(1(6,62)$0</2,'26,6
Precursor protein is stimulated to be transformed 
into amyloid protein due to high level in serum or 
gene mutation which is prone to misfolding.There are 
also protein having intrinsic tendency to be amyloid 
protein with slower late, such as transthyretin in senile 
amyloidosis. Once stimulated protein interacts with 
extracellular environment, proteolysis might occur 
and it binds to matrix component (glycosaminoglycan 
DQG FROODJHQ IDFLOLWDWLQJ DJJUHJDWLRQ LQWR ¿EULODU
amyloid protein. In this mechanism, extracellular 
chaperone protein act to prevent aggregation and serum 
P amyloid will bind to amyloid protein and protect it 
from reabsorption10
The amyloid protein will result in cell injury, tissue 
damage, and organ dysfunction through mechanism 
that is not fully understood. The damage might be 
due to direct precursor protein before being amyloid 
protein (e.g. light chain immunoglobulin) or after being 
amyloid protein deposit.10 In gastrointestinal amyloid, 
WKH DP\ORLG SURWHLQ FDQ LQ¿OWUDWH HLWKHUPXFRVD RU
QHXURPXVFXODU VWUXFWXUH0XFRVDO LQ¿OWUDWLRQPRVW
commoly occur in the descendent part of duodenum 
(100%), stomach and colorectum (more than 90%), 
and esophagus (around 70%).11Blood vessel is usually 
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affected in the small bowel. Occlusion of the vessel 
will result in bowel ischemia and infarct.3,11
)LJXUH3DWKRJHQHVLVRIDP\ORLGRVLV
)LJXUH%LRSV\UHVXOWRIGXRGHQXPPXFRVDHQGRVFRS\XVLQJ
UHG&RQJRVWDLQ±DUURZSRVLWLYHVWDLQLQJDW ODPLQDSURSULD
DQGEORRGYHVVHO
JDVWURLQWHVWLQDO WUDFW7KHHWLRORJ\RI WKLV¿QGLQJ LV
still unknown.13
Neuromuscular infiltration starts with nerve 
LQ¿OWUDWLRQUHVXOWLQJLQFRQWUDFWLRQDEQRUPDOLW\ZLWK
normal amplitude and uncoordinated frequency. 
$V WKH GLVHDVH SURJUHVVHV WKHPXVFOH LV LQ¿OWUDWHG
leading to muscle atrophy and decreased in contraction 
amplitude. Therefore, the bowel transit time is longer. 
Although there is no study in gastrointestinal motility in 
amyloidosis patient available at present, neuromuscular 
LQ¿OWUDWLRQXVXDOO\LQGXFHVVWDVLVV\QGURPH3,12,13
7KH OHYHORIQHUYHDQGPXVFOH LQ¿OWUDWLRQYDULHV
depend on the type of amyloidosis. One study evaluated 
16 patients having amyloidosis and intestinal pseudo 
obstruction (13 AA, 2 AL,1 dialysis associated 
amyloidosis). Patients with AA had tendency of having 
amyloid protein deposit in Auerbach plexus without 
PXVFOH LQ¿OWUDWLRQZKLOH RWKHU SDWLHQWV KDGGLIIXVH
DQG H[WHQVLYH LQ¿OWUDWLRQRIPXVFOH OD\HU DORQJ WKH
&/,1,&$/0$1,)(67$7,21
A symptomatic gastrointestinal amyloidosis patient 
usually come with one of these four syndomes: (1) 
Gastrointestinal hemorrhage due to fragile blood 
vessel or mucosal lesion; (2) Chronic intestinal 
GLVPRWLOLW\ GXH WR LQ¿OWUDWLRQ RI VPRRWKPXVFOH LQ
the gastrointestinal tract. The clinical manifestation 
consists of dysphagia, gastroparesis, constipation, or 
chronic intestinal pseudo obstruction. Dysmotility 
causing shortening of intestinal transit time might also 
cause diarrhea; (3) Malabsorption due to neuromuscular 
LQ¿OWUDWLRQLVFKHPLDEDFWHULDORYHUJURZWKSDQFUHDWLF
LQVXI¿HFLHQF\ DP\ORLGSURWHLQ LQ¿OWUDWLRQ LQ EORRG
vessel or pancreatic acini tissue). This syndrome is 
found in 8.5% AL patient and 23% AA patient. The 
clinical manifestation consists of weight loss, diarrhea, 
steatorrhea, anorexia, hypotension or orthostatic 
changes; (4) Gastroenteropathy with protein loss with 
edema as the clinical manifestation.3,8,14
The most frequent clinical manifestation in all 
patients are weigh loss (45%) and gastrointestinal 
bleeding (36%).6,14 Esophageal disease in amyloidosis 
has symptoms such as dysphagia, chest pain, heart 
burn, and hematemesis. The most common radiography 
finding are atony and widening esophagus with 
decreased peristaltic, sometimes with narrowing in the 
distal part and widening in the proximal part, linked 
ZLWKWUDFKHREURQFKLDODVSLUDWLRQ/HVVFRPPRQ¿QGLQJ
is ulcer or mass. Various manometry abnormality 
can bee seen in esophagus. Frequent manometry 
abnormality can be seen in the esophagus. The pressure 
of lower esophageal sphincter is usually normal or low, 
and accompanied with heart burn. The prevalence of 
esophageal amyloidosis varies from 13% in a radiology 
study to 22% in an autopsy report.6
)LJXUH  *DVWURLQWHVWLQDOPDQRPHWU\ LQ \HDU SULPDU\
DP\ORLGRVLVSDWLHQW±ORZDPSOLWXGHRIFRQWUDFWLRQLQDOOOHYHO
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In amyloidosis patient, stomach involvement occur in 
8% of patients according to biopsy and 12% of patients 
according to autopsy, with only 1% of patients are 
symptomatic. The symptoms of stomach involvement 
are nausea, vomiting, hematemesis, and epigastric pain. 
Obstruction of gastric outlet, thickening of gastric fold, 
gastric ulcer, hematoma, artery vein malformation, 
granular appearance of mucosa, plaque-like lesion, 
and gastroparesis can occur infrequently.6 Stomach 
amyloidosis may also manifest as gastric perforation, 
JDVWURFRORQ¿VWXODDQGJDVWULFPDOLJQDQF\15
The most common site of amyloid deposit is in the 
small intestine, which is 31% of patients according to 
autopsy. Patient with small intestine amyloid might 
come with diarrhea, steatorrhea, protein loss, bleeding, 
obstruction, infarct, perforation, intussusception, 
intestinal pneumatosis, and constipation. Some amyloid 
patients may also have malabsorption symptom.6,16 
Clinical manifestation of amyloid deposit in colon 
FDQUHVHPEOHRWKHUGLVHDVHV LQFOXGLQJ LQÀDPPDWRU\
bowel disease, malignancy, ischemic colon, and 
collagenous colitis. The complications are colon 
dilatation, pseudo obstruction, stricture formation, 
rectal bleeding, submucosal bleeding, volvulus, infarct, 
and perforation.6,14
' ,$*126 , 6  2)  *$6752 ,17(67 , 1$/
$0</2,'26,6
Diagnosis of gastrointestinal amyloidosis is quite 
GLI¿FXOW*DVWURLQWHVWLQDODP\ORLGRVLVLVVXVSHFWHGLQ
the following conditions: (1) Patient having disease 
which is known associated with amyloidosis, such 
DVPXOWLSOHP\HORPDFKURQLFLQÀDPPDWLRQGLVHDVH
chronic kidney failure on hemodialysis treatment; 
(2) Patient having organ disorder typically for 
accumulation of amyloid protein, such as: nephritic 
syndrome, unexplained heart failure, carpal tunnel 
V\QGURPHMRLQWLQÀDPPDWLRQLQGLDO\VLVSDWLHQW
Since AL is the most frequent etiology of 
gastrointestinal amyloidosis, it is suggested that initial 
examination includes light chain immunoglobulin 
examination. This, can be done through urine or serum 
SURWHLQHOHFWURSKRUHVLVXULQHRUVHUXPLPPXQR¿[DWLRQ
or serum light chain immune nephelometry method. 
Using these 3 methods of examination will yield 99% 
of sensitivity.15 Bone marrow aspiration and biopsy 
might be performed to look for plasm cell malignancy 
if AL is suspected in negative urine and serum protein 
electrophoresis.16
Endoscopic biopsy of gastrointestinal tract 
is diagnostic in most cases of amyloidosis. The 
highest degree of amyloid protein deposit over all 
of gastrointestinal tract is in the duodenum. Various 
mucosal abnormalities are found in endoscopy of 
JDVWURLQWHVWLQDOWUDFW/HVLRQPD\DSSHDUDV¿QHJUDQXODU
mucosal granular and nodular, polypoid protrusion, 
erosion, ulceration, fragile mucosa and thickening of 
bowel wall. Macroscopically, AL usually has polypoid 
protrusion while AA has granular mucosa.17 Some 
patients have deposit of amyloid protein forming a 
tumor called amyloidoma. Amyloidoma can be found at 
anywhere in the gastrointestinal tract. Focal amyloidoma 
in duodenum and jejunum have ever been described as 
extensive deposit of amyloid involving all layers of the 
bowel wall.18
)LJXUH  *UDQXODU DQG QRGXODU OHVLRQ LQ WKH GXRGHQXP 
7KHPXFRVDLVIUDJLOHDQGHDVLO\EOHHG
&RQ¿UPDWLRQ RI DP\ORLG SURWHLQ GHSRVLW LQ WKH
biopsy specimen can be done using Conge red staining. 
Direct fast scarlet staining can show typical red 
appearance in normal lighting and birefringens green 
apple in light polarization. Both indicate a prominent 
mucosal deposit of amyloid.6 The biopsy must be deep 
enough (especially for AL) in order to acquire the 
ODPLQDSURSULDOD\HUVLQFHELUHIULQJHQVLVEHVWLGHQWL¿HG
at blood vessel wall.16
)LJXUH  'LUHFW IDVW VFDUOHW VWDLQLQJ VKRZV D W\SLFDO UHG
DSSHDUDQFH LQQRUPDO OLJKWLQJ OHIW DQGELUHIULQJHQVJUHHQ
DSSOHLQOLJKWSRODUL]DWLRQULJKW
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To get overall image of amyloid deposit in the body, 
serum amyloid P with I123 label can be injected into the 
FLUFXODWLRQ,WELQGVZLWKERG\¿EULODUDP\ORLGSURWHLQ
The sensitivity of this scintigraphy diagnostic is 90% 
for AA and AL.6
Radiography examination using Barium has 
OLPLWHGGLDJQRVWLFYDOXHGXHWRXQVSHFL¿F¿QGLQJIRU
amyloidosis, such as: (1) AA: coarse mucosal pattern 
ZLWK¿QHJUDQXODUHOHYDWLRQPRVWO\GXHWRH[SDQVLRQRI
lamina propria due to deposition of amyloid protein; (2) 
$/SRO\SRLGSURWUXVLRQDQGWKLFNIROGLQJZKLFKUHÀHFW
massive amyloid protein deposit in the smoot muscle 
layer; (3) Amyloid associated with dialysis: small bowel 
and colon dilatation due to smooth muscle deposit of 
amyloid protein causing prolonged transit time.19
3URSHUFODVVL¿FDWLRQLVDQLPSRUWDQWWKLQJ6\VWHPLF
chemotherapy can effectively treat AL patient. Localized 
amyloidosis does not require systemic therapy due 
to good long term prognosis.15 Organ such as bone 
marrow, kidney, heart, intestine, lung, and joint are 
almost involved in the systemic amyloidosis. Therefore, 
systemic amyloidosis can be excluded if no amyloid 
protein deposit found in organ biopsy. Moreover, to 
diagnose localized amyloidosis, paraproteinemia is 
EHVWWREHH[FOXGHGWKURXJKLPPXQR¿[DWLRQ8
)LJXUH1RQVSHFL¿FVPDOOLQWHVWLQHORRSGLODWDWLRQWKLQDUURZ
DQGVWULFWXUHDWGXRGHQDOORRSWKLFNDUURZLQ$$SDWLHQW
75($70(172)$0</2,'26,6
*DVWURLQWHVWLQDOFRPSOLFDWLRQFDQFDXVHVLJQL¿FDQW
pain but usually will not cause death. Mortality 
is more common due to kidney failure, restrictive 
cardiomyopathy, or ischemic heart disease. The 
principle of management of amyloidosis should be 
directed at controlling gastrointestinal symptoms 
using symptomatic therapy, stopping the formation 
and deposit of amyloid protein, and treating the 
%LRSV\DQGKLVWRSDWKRORJ\XVLQJ&RQJRUHGVWDLQULVNRIEOHHGLQJ
&OLQLFDOVXVSLFLRQRIJDVWURLQWHVWLQDODP\ORLGRVLV
6\PSWRPVDEGRPLQDOSDLQGHFUHDVHGLQDSSHWLHKHPDWHPHVLVKHPDWRVFKH]LDDQHPLDZHLJKW
ORVV
5DGLRORJ\PXFRVDODEQRUPDOLW\XOFXVJDVWULFFDUFLQRPDDSSHDUDQFHVFLUURXVW\SH
(QGRVFRS\DEQRUPDOEOHHGLQJHURVLYHJDVWULWLVXOFXVLUUHJXODUPXFRVDOWKLFNHQLQJ
&RPRUELGLW\PXOWLSOHP\HORPDRURWKHUSDUDSURWHLQHPLDVO\PSKRPDFDUFLQRPDRWKHUFKURQLF
GLVHDVHVVXFKDVUKHXPDWRLGDUWKULWLV
(YDOXDWLRQRIV\VWHPLFDP\ORLGRVLV
$QDPQHVLV DQG SK\VLFDO H[DPLQDWLRQ IDPLO\ KLVWRU\ QHSKURWLF V\QGURPHPDFURJORVLD SXUSXUD
FDUGLRP\RSDWK\
/DERUDWRU\
EORRGKHPRJORELQFUHDWLQLHDOEXPLQELOLUXELQDONDOLQHSKRVSKDWDVHUKHXPDWRLGIDFWRU
XULQHFUHDWLQLQHFOHDUDQFHWHVW&&7%HQFH-RQHVSURWHLQ
VHUXPDQGXULQHHOHFWURSKRUHVLVDQGLPPXQR¿[DWLRQ
(OHFWURFDUGLRJUDSK\(&*HFKRFDUGLRJUDSK\
%LRSV\IURPRWKHURUJDQVQRQJDVWURLQWHVWLQDOERQHPDUURZOLYHUNLGQH\
5DGLRORJ\FRPSXWHUL]HGWRPRJUDSK\&7VFDQRUPDJQHWLFUHVRQDQFHLPDJLQJ05,RIWKRUD[DQG
DEGRPHQ
,IDYDLODEOHJHQHWLFH[DPLQDWLRQJHQHWLFPXWDWLRQWUDQVWK\UHWLQ775VFLQWLJUDSK\XVLQJ,
6\VWHPLFLQYROYHPHQW
6\VWHPLFDP\ORLGRVLV
ZLWKJDVWURLQWHVWLQDOLQYROYHPHQW
/RFDOL]HGJDVWURLQWHVWLQDO
DP\ORLGRVLV
1R <HV
)LJXUH'LDJQRVLVDOJRULWKPRIJDVWULFORFDOL]HGDP\ORLGRVLV
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underlying diseases. This approach can result 
stabilization or improvement of function of the 
affected organ.6 The goal in AL treatment is to reduce 
light chain immunoglobulin production through 
chemotherapy. Recently, high dose chemotherapy 
using melphalan 200 mg/m2 and prednisone combined 
with stem cell transplantation to treat AL resulted in 
increase of survival rate.15
AA patient can have stabilization or improvement 
if the underlying disease (rheumatoid arthritis, Crohn’s 
disease, etc) is well controlled so that the production 
of serum amyloid A can be controlled. Patient having 
severe intestinal amyloidosis due to aggressive 
rheumatoid arthritis can be treated using tocilizumab, 
an interleukin 6 anti reseptor antibody. This therapy 
results in improvement of gastrointestinal symptoms 
and systemic joint pain. Moreover, AA serum protein 
level can be reduced back to normal range and repeat 
endoscopic biopsy show no amyloid accumulation 
in the colon. Tocilizumab can be the drug of choice 
in treatment of AA associated with inflammatory 
arthritis. A new-small molecular inhibitor, R-1-[6- 
[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexa-noyl]
pyrrolidine-2 carboxylic acid (CPHPC) has been 
developed to specifically attack serum amyloid P 
component which is a universal constituent of amyloid 
deposit and contributes to its formation. CPHPC 
reduced serum amyloid P and ceased the amyloid 
deposit in a systemic amyloidosis study. Unfortunately, 
WKDW SURPLVLQJ VSHFL¿F DJHQW RI WUHDWPHQW KDV QRW
been yet available in clinical setting. In practical, AA 
amyloidosis treatment is to control the primary disease. 
For example, extending anti tuberculosis treatment 
could reduce amyloidosis in a report. Chlorambucil and 
WXPRUQHFURVLVIDFWRUĮLQKLELWRUXVHGLQLQÀDPPDWRU\
arthritis therapy would reduce the amyloid deposit. 
Colchicine, alkaloid extracted from Colchicum 
autumnale, family of lily plant, is prescribed to treat 
diseases such as gout, Behcet’s disease, and primary 
biliary cirrhosis. This drug inhibits the formation of 
microtubule, affects cellular mitosis, and interferes 
with the phagositic ability of PMN cell. Colchicine 
is presently used as an effective drug to prevent and 
treat amyloidosis secondary to FMF. In an initial study, 
colchicine (1.5 mg/day) was given to treat nephropathy 
amyloid in patient with dystrophic type of inherited 
bullous epidermolysis. Recently, it is reported that 
gastrointestinal amyloidosis secondary to bullous 
epidermolysis was cured using colchicines in the same 
dose in the next 2 months.6,10
Liver transplantation is an effective method to 
treat hereditary amyloidosis. Abnormal transthyretin 
in hereditary amyloidosis is produced by liver, so that 
liver transplantation will result in normal production 
of transthyretin.6 Gastrointestinal complication can be 
treated with symptomatic control. It is important to 
ensure adequate nutrition and hydration. For example, 
gastroparesis symptom can be effectively treated 
using metoclopramide or domperidone. Neostigmine 
can relieve acute pseudo-obstruction of colon, and 
can be used as an alternative to decompress the colon 
in patient with acute medical condition. Diarrhea 
can be treated using loperamide or octreotide.3 Total 
parenteral nutrition can be used in severe dysmotility 
and patient is in malnutrition. Antibiotic is used to treat 
bacterial overgrowth. It is better for the patient to get 
supplementation, especially fat-soluble vitamin. The 
treatment of gastrointestinal bleeding is the same as 
in other diseases.6
352*126,62)$0</2,'26,6
Median survival rate of 868 AL patients in Pavia 
center was 3.8 years, of which 27% of patients died in 
¿UVW\HDUDIWHUGLDJQRVHGDQGFXPXODWLYHSURSRUWLRQ
of 10-year survival rate was 31%. Mortality was 
due to cardiac amyloidosis in 75% of dead patients. 
Therefore, the determinant of amyloidosis output was 
the magnitude of cardiac involvement.10
&21&/86,21
Amyloidosis is a pathologic process caused by 
GHSRVLWRI¿EULOODUDP\ORLGSURWHLQLQWKHH[WUDFHOOXODU
space. Diagnosis of gastrointestinal amyloidosis is 
TXLWHGLI¿FXOW(QGRVFRSLFELRSV\RIJDVWURLQWHVWLQDO
tract is diagnostic in most cases of amyloidosis. 
&RQ¿UPDWLRQRIDP\ORLGSURWHLQGHSRVLWLQWKHELRSV\
specimen can be done using Congo red staining. The 
principle of management of amyloidosis should be 
directed at controlling gastrointestinal symptoms 
using symptomatic therapy, stopping the formation and 
deposit of amyloid protein, and treating the underlying 
diseases.
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